Fusen Pharmaceutical Wins China Approval for New Lornoxicam Injection

Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has issued an announcement.

Fusen Pharmaceutical has secured Chinese regulatory approval to market its Lornoxicam for Injection, developed by its wholly owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, for the short-term treatment of moderate acute post-operative pain. The non-steroidal analgesic, already classified as a Class B drug under the national reimbursement system and endorsed by multiple domestic clinical guidelines, offers morphine-comparable pain relief with fewer side effects and lower addiction risk, positioning it as a preferred component of multimodal perioperative analgesia and expanding Fusen’s anti-inflammatory and pain-management portfolio in a domestic market where sales of similar injections exceeded RMB300 million in 2025.

The launch of Lornoxicam for Injection adds an important new product to Fusen’s portfolio and strengthens its presence in China’s hospital-based pain management market. By aligning with authoritative treatment guidelines and tapping into a sizable and growing market for perioperative analgesia, the company aims to broaden therapeutic options for post-surgical and acute pain patients while enhancing its competitive standing in non-opioid analgesics.

More about Fusen Pharmaceutical Co., Ltd.

Fusen Pharmaceutical Company Limited is a Cayman Islands-incorporated drug maker listed in Hong Kong, focused on developing and marketing pharmaceutical products in China. Through subsidiaries such as Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, the group builds a pipeline in therapeutic areas including anti-inflammatory and analgesic medications targeting hospital and clinical use.

Average Trading Volume: 604,740

Technical Sentiment Signal: Buy

Current Market Cap: HK$860.2M

For an in-depth examination of 1652 stock, go to TipRanks’ Overview page.